Antineo
keyboard_backspaceBack to Home
Contact
Bâtiment Bioserra 2, 2e étage, 60F avenue Rockefeller
69008 Lyon
France
Directrice des études scientifiques et du développement commercial
About us
Antineo is a contract research organization providing services in preclinical therapeutic research in oncology We offer services to customers wishing to evaluate the antitumor activity of their compounds in the most relevant models, either as single agents or in combination with standard therapies, as well as in models resistant to conventional treatment. Our services include personalized advice and dedicated expertise to determine the most relevant models and to optimize the preclinical strategy for your future clinical development. Our services are provided by a team with international level expertise in onco-pharmacology.
Business offer
Antineo's business is based on providing services for the evaluation of new anti-cancer compounds (small molecules, antibodies, peptides, etc.). The company provides scientific consultancy and supports its customers in optimizing the development of their anti-cancer compounds through a range of services from in vitro (cell toxicity, sample characterization) to in vivo (anti-tumor efficacy, toxicity, pharmacokinetic studies) and ex vivo services (determination of mechanism of action or target by flow cytometry).
The company has a library of over 150 human and murine tumor cell lines, representative of different types of cancer (colon cancer, breast cancer, cancer mutated for a particular gene, etc.).
Antineo also has an R&D activity through which the company develops original models of resistance to reference therapies, notably immune checkpoint inhibitors, currently available on the market to assess the efficacy of new anti-cancer therapies, as well as in vitro models of 3D-printed tumors.
Activities
- Service
- Oncology
- Hematology
- Immunology
- Target selection & validation
- Expression and pathway analysis of target
- quantification of target
- Assay development in in-vitro & in-vivo models
- Immunotherapy lead generation
- Binding & Affinity
- Potency & Specificity
- Functional effects
- ADCC, ADCP & CDC
- Antigen density target
- Internalization
- Pharmacology & Biological activity
- PK/PD bioavailability
- Mode of Action
- Therapeutic efficacy
- Safety
- Immunotoxicology
- Specificity
- Cell activation
- Avidity testing
- Cell-based activation (APCs, AAPCs)
- Bead-base activation
- Antibody-based activation
- Ex-vivo activation (cell transfer)
- In-vivo activation (in human transgenic mouse models)
- Gene modification / Transduction
- Retroviral & lentiviral vectors
- mRNA electroporation
- CRISPR/Cas9
- Immunotherapy lead optimization
- Indication Prioritization
- Proof of concept
- Pharmacology potency
- Exploratory toxicology
- in-vitro & ex-vivo models
- in-vivo models
- CMC
- GLP compliance
- Master Cell Bank
- Production
- Cell Line development
- Clone selection
- Characterization
- Storage
- Analytical development
- Cell Culture
- Gene modification / Transduction
- Retroviral & lentiviral vectors
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- Target Identification
- Expression and pathway analysis of target
- quantification of target
- Assay development in in-vitro & in-vivo models
- Adoptive T Cell Major Challenges in Solid Tumors
- Tumor/Ag heterogeneity
- Tumor associated Antigen
- Microenvironment
- Delivery/homing
- Combinations
- Persistence of CAR-T
- In vivo proliferation and activation of CAR-T
- Accessibility of tumor cells
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
